



We are writing to you with important information regarding ZINBRYTA® (daclizumab).

Biogen, with our partner AbbVie, has decided to voluntarily withdraw ZINBRYTA from the market. ZINBRYTA will no longer be available as of [April 30, 2018](#).

Due to the increasingly complicated benefit/risk profile of ZINBRYTA, we believe it is in the best interest of patients to withdraw ZINBRYTA. There are complicated types of adverse events being reported in patients taking ZINBRYTA. All adverse event reports, including new reports, continue to be evaluated.

We understand this may have a significant impact on you, and that you may have questions. If you are currently taking ZINBRYTA, please contact your healthcare provider as soon as possible to discuss a new treatment plan that is right for you. If you and your healthcare provider decide to continue with ZINBRYTA during the transition period, you may receive a maximum of one additional dose, between now and April 30, 2018.

It is still important that you continue monthly liver monitoring during treatment and monthly for 6 months after your last dose of ZINBRYTA, even if you are feeling well. The ZINBRYTA Lab Assist Program will remain available over the coming months to assist you and your healthcare provider with your monthly liver monitoring needs. In addition, please contact your healthcare provider right away if you have any new or unexplained symptoms affecting any part of your body while taking ZINBRYTA, and for 6 months after your last dose.

Your healthcare provider is your best resource for information about the next steps for your therapy.

Please call us at [1-800-456-2255](tel:1-800-456-2255) if you have any questions.

Thank you,
Biogen